NCT00938652_2A: NCT00938652, figure 2A

NCT00938652_2AR Documentation

NCT00938652, figure 2A

Description

Kaplan-Meier digitized data from NCT00938652, figure 2A (PMID 25349301). A reported sample size of 519 for a primary endpoint of OS/PFS in breast cancer.

Usage

NCT00938652_2A

Format

A data frame of 519 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (gc, gci)

Source

O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32: 3840–7.

Examples

summary(NCT00938652_2A)

kmplot(NCT00938652_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.